Introduction

O
6 -methylguanine (O 6 MeG) is a highly toxic and mutagenic lesion formed in DNA by S N 1 alkylating agents. This lesion is efficiently repaired by O 6 -methylguanine DNA methyltransferase (MGMT) through direct transfer of the adducted methyl group to the sulfur of the active site cysteine in MGMT (Fang et al., 2005) . This irreversible reaction renders MGMT inactive for further repair and induces a conformational change, whereby MGMT is targeted for ubiquitindependent degradation (Xu-Welliver and Pegg, 2002) . O
6
MeG slows but does not block DNA replication and is highly mutagenic because it preferentially mispairs with thymine, ultimately causing GC-AT transition mutations (Snow et al., 1984; Larson et al., 1985) . The toxicity of the O 6 MeG lesion is attributed to the recognition of O 6 MeG:T mispairs by the DNA mismatch repair machinery (Karran and Bignami, 1992) . The nascent thymine is removed during mismatch repair processing, but another thymine is likely inserted opposite the unrepaired O 6 MeG serving to reinitiate mismatch repair processing. This cycle of 'futile repair' can lead to chromosomal aberrations, cell-cycle arrest or apoptosis (Kat et al., 1993; Hickman and Samson, 1999; Kaina, 2003) .
MGMT is highly conserved phylogenetically, and yeast cells mutated for the MGMT homolog, Mgt1, have higher spontaneous mutation rates than wild-type cells (Xiao and Samson, 1993) . Although MGMT deficiency has not been shown to increase spontaneous mutation rate in cultured mammalian cells, wild-type cells have a smaller fraction of spontaneous G-A transition mutations compared with mutant cells (Aquilina et al., 1992) . Similarly, Mgmt null mice show little increase in spontaneous mutation or spontaneous tumor susceptibility, but are extremely sensitive to the cytotoxic and carcinogenic effects of alkylating agents (Sakumi et al., 1997; Glassner et al., 1999; Sandercock et al., 2004) . Sekiguchi and co-workers showed that methylnitrosourea-induced, O 6 MeG-dependent lethality in mice is relieved by the addition of a DNA mismatch repair deficiency, but at the expense of increased thymic lymphoma development (Sakumi et al., 1997) . However, this model of alkylation tolerance/tumor susceptibility has not been shown at other anatomic sites. Here, we used mice with a targeted deletion of the Mgmt active site region to monitor the effect of unrepaired O 6 MeG lesions on intestinal cancer susceptibility and to examine the interaction with DNA mismatch repair (Glassner et al., 1999) . MGMT may be important in protecting against sporadic human colorectal cancer, as its expression is lost through epigenetic silencing of the MGMT gene in nearly 50% of these cancers (Lind et al., 2004) . Strengthening the argument for a causal association, tumors with silenced MGMT tend to have higher incidences of GC-AT transitions in KRAS2 and TP53 (Esteller et al., 2001; Nagasaka et al., 2008) . Inhibition of MGMT with O 6 -benzylguanine in rats sensitizes to azoxymethane (AOM)-induced colon tumors, and transgenic expression of Mgmt in mice protects against AOM-induced aberrant crypt foci (ACF) (Zaidi et al., 1995; Wali et al., 1999) . In this study, we examined the interaction of Mgmt with the mismatch repair gene Msh6 in different models of intestinal tumorigenesis. Both genes are ubiquitously expressed, and Msh6-deficient mice develop spontaneous intestinal tumors at approximately 1 year of age (Myrnes et al., 1984; Harris et al., 1991; Acharya et al., 1996; Edelmann et al., 1997) . We found that Mgmt À/À mice are sensitive to AOM-induced ACF and that this sensitivity is synergistically enhanced in Msh6 À/À mice. Furthermore, the effect of Msh6 on this carcinogen-induced end point could be explained entirely by its suppression of apoptosis. However, although Msh6-mediated apoptosis was sufficient to account for the suppression of O 6 MeG-induced ACF formation, it did not result in suppression of adenoma formation in a chronic inflammation-dependent model of tumorigenesis.
Results
Mgmt and Msh6 act synergistically to suppress ACF formation in response to AOM To determine whether Mgmt protects against alkylation-induced cancer or precancerous ACF, we treated mice with a single dose of the carcinogen AOM. The dose of 10 mg/kg was chosen, because it yields a modest number of ACF in wild-type C57BL6/J mice (Sohn et al., 2001) . On this resistant genetic background, numerous ACF will form after five consecutive weekly treatments with AOM, but only a small fraction of these will progress to adenomas. We attempted successive weekly doses to induce tumors, but all the Mgmt À/À died during the course of treatment (data not shown). AOM is an S N 1 alkylating agent whose mutagenicity is dependent on activation by mixed function oxidases of the cytochrome p450 superfamily (primarily Cyp2e1) causing breakdown to the ultimate carcinogen, the methyl diazonium ion (Sohn et al., 2001) . Following treatment with 10 mg/kg AOM and euthanization 15 weeks after treatment, Mgmt À/À mice developed ninefold more ACF than wild-type mice (Po0.0001), and Msh6 À/À mice developed fourfold more ACF than wild-type mice (P ¼ 0.003) (Figure 1b ). The effect of combining both mutant alleles on ACF formation was nearly perfectly multiplicative, with Mgmt
Msh6
À/À animals developing 38-fold more ACF than wild-type mice (Figure 1b) . Also, the number of ACF did not change from 15 to 25 weeks, as wild-type and Mgmt À/À animals that were killed at 25 weeks after treatment had nearly identical average ACF numbers compared with the respective groups at the 15-week time point (Figure 1b) . Importantly, Mgmt heterozygosity also caused a significant 3.3-fold increase in ACF multiplicity relative to wild type (P ¼ 0.03) (Figure 1c 
þ /À mice euthanized 15 weeks after treatment each had a single adenoma, and no tumors were seen in either the Mgmt þ / þ or Mgmt À/À mice euthanized 25 weeks after AOM treatment. This result is consistent with the resistance of C57BL6/J mice to tumor development in response to AOM, and shows that Mgmt deficiency does not significantly affect progression to adenomas in this experimental time frame.
Mgmt deficiency enhances AOM-induced apoptosis
To examine the short-term cytotoxic effect of the carcinogen AOM, apoptosis was scored in the colon 24 and 48 h after a single injection; Figure 2 shows one representative photomicrograph of colonic apoptosis after AOM treatment in a Mgmt À/À animal (see arrows). Over 90% of the total apoptoses in any group occurred within five cells from the base of the crypt (data not shown). Mgmt À/À mice were dramatically more sensitive to AOM-induced apoptosis than wild-type mice. The sensitivity of the Mgmt À/À strain is apparent at 24 h post AOM for the 10 mg/kg dose ( Figure 2b ) and by 48 h after the same dose Mgmt À/À mice had an apoptotic index 20-fold greater than that of wild-type mice, with Mgmt À/À mice showing 1.2 ± 0.2 apoptoses per crypt, and wild-type mice showing 0.05±0.02 apoptoses per crypt ( Figure 2c ). In fact, even Mgmt À/À animals treated with 1 mg/kg AOM still had over a 10-fold higher apoptotic index than that of wild-type mice treated with 10 mg/kg AOM. The sensitivity of Mgmt À/À mice to AOM-induced apoptosis was entirely rescued by Msh6 deficiency (Figures 2b and c) . After 48 h of exposure to 10 mg/kg AOM, the double-mutant Mgmt
mice had an apoptotic index indistinguishable from either wild-type or Msh6 À/À mice, and 20-fold lower than Mgmt À/À mice ( Figure 2c ). Differences in apoptotic index among genotypes were consistent between the 24 and 48-h time points (compare Figures 2b and c) . The apoptotic response of Mgmt À/À mice was lower and was more variable at the 24-h versus the 48-h time point for all genotypes. This variability may be explained by the fact that O 6 MeGdependent apoptosis occurs in the second cell cycle after adduct formation, and cells at the base of the crypt in the colon divide approximately once a day (Kellett et al., 1992; Kaina et al., 1997) ; thus, at the 48-h time point, the majority of dividing cells would have completed two cell cycles. At 48 h after a dose of 50 mg/kg, Mgmt À/À mice were again scored as being more sensitive to apoptosis than wild-type mice, and again the sensitivity was relieved by Msh6 deficiency. At this dose, however, the magnitude of the difference between Mgmt À/À and other genotypes was not as great as that at 10 mg/kg, possibly because of the induction of apoptosis by lesions other than O 6 MeG. This is consistent with the observed rise in apoptotic index only in Mgmt À/À mice from 24 to 48 h after treatment in contrast to a leveling or decline in the other genotypes (Figures 2b and c) . Mgmt-deficiency sensitizes to tumorigenesis when tumors are promoted with dextran sulfate sodium To determine whether Mgmt deficiency can sensitize animals to colon tumor development, mice were treated with a classic two-stage colon carcinogenesis protocol: namely, a single injection of AOM followed by repeated exposure to dextran sulfate sodium (DSS) in the drinking water. Oral delivery of DSS to mice injures the colonic epithelial barrier resulting in inflammation, and tumor promotion associated with this inflammation occurs almost exclusively in the mid-to-distal colon. Following treatment with 1 mg/kg AOM þ DSS, Mgmt À/À mice developed ninefold more tumors than Mgmt þ / þ mice (P ¼ 0.003) (Figure 3a ). Histopathologic analysis of tumors showed polypoid or sessile adenoma with moderate-to-severe dysplasia and frequent mitoses. No differences in histopathology were observed among different genotypes (data not shown). The combination of 5 mg/kg AOM followed by DSS treatment was highly toxic to Mgmt À/À mice, and 12 days after termination of the first cycle of DSS, only 2 of 15 Mgmt À/À mice survived (Figure 3b) 
Msh6
À/À mice showed full survival during this period. Paralleling the apoptosis results, the addition of Msh6 deficiency to the Mgmt À/À background completely eliminated whole-animal lethality induced by 5 mg/kg AOM, followed by DSS administration. The two surviving Mgmt À/À animals had more tumors than Mgmt þ / þ mice at the end of the study (Figure 3c ). The double-mutant Mgmt À/À
À/À mice had 27-fold more tumors than wild-type mice (P ¼ 0.02). Thus, the induction of tumors did not parallel the induction of ACF (Figure 1c) , as the tumor response of Mgmt
À/À mice did not significantly differ from that of Msh6 À/À mice (Figure 3c ). Min/ þ mice were 1.8 and 1.9-fold higher, respectively, compared with Mgmt þ / þ Apc Min/ þ mice, but neither difference was statistically significant (P ¼ 0.08 and 0.13, respectively). Furthermore, the results in Figure 4 represent a combination of data from two independent experiments, and the small and statistically insignificant fold differences in tumor multiplicity could be attributed to a modest, between-experiment difference in tumor response (data not shown). Moreover, there was no effect of Mgmt on tumor size or on tumor distribution throughout the length of the intestine (Figures 4b and c) .
Mgmt does not affect tumor formation in
Discussion
Our studies show that Mgmt deficiency sensitizes animals to the development of colonic ACF after treatment with an exogenous alkylating agent, and also sensitizes to the development of colorectal adenomas when this alkylation is followed by inflammationassociated tumor promotion. In fact, the magnitude of the difference between Mgmt À/À and wild-type mice for ACF following AOM treatment was exactly the same as the difference in tumor multiplicity following AOM þ DSS. Almost all tumors that develop after AOM þ DSS treatment have GC-AT transition mutations in the b-catenin oncogene, Ctnnb1. This type of mutation is caused by AOM and prevented by Mgmt, and thus it is possible that Mgmt deficiency is increasing the AOM-induced mutation frequency in Ctnnb1. In addition, Mgmt and Msh6 had a synergistic effect on suppressing AOM-induced ACF, a synergy that can be explained entirely by the Msh6 deficiency relieving the sensitivity to AOM-induced apoptosis on an Mgmt À/À background. Mismatch repair has been shown to trigger apoptosis in response to several types of DNA damage (Stojic et al., 2004; Jiricny, 2006) . Loss of this function allows cells to survive in the presence of damage, increasing the chances of accumulating oncogenic mutations. The results of our study show that for the end point of alkylation-induced ACF formation, this mechanism is sufficient to explain the observed increase of ACF in Mgmt À/À Msh6 À/À mice relative to Mgmt À/À mice. Our results also show the enormous sensitivity of Mgmt-deficient animals to alkylation-induced carcinogenesis. Mgmt-deficient mice had a 20-fold higher apoptotic index at the dose of AOM used in the carcinogenesis experiments. Potentially, 20-fold more would-be-initiated cells are removed by apoptosis from the colonic crypts, and still Mgmt À/À mice developed ninefold more ACF.
The mechanism for Msh6-suppressing adenoma formation following AOM þ DSS treatment is somewhat different than for AOM-induced ACF:
mice had a greater tumor response than Mgmt þ / þ mice and the two surviving Mgmt À/À animals, but the response was similar to mice deficient for Msh6 alone. Our data do not rule out the possibility that initiated cells that go on to form ACF are qualitatively different from those that form adenomas. Another possible explanation for our results is that replication errors that occur during IBD-associated cell proliferation are driving mutagenesis and tumor development in Msh6-deficient mice to a point that mutations resulting from O 6 MeG do not further enhance tumor development. Our results are consistent with previous reports showing the extreme sensitivity of mismatch repair-deficient mice (Msh2 À/À and Mlh1 À/À ) to IBDassociated tumor development caused by DSS administration (Kohonen-Corish et al., 2002; Taniguchi et al., 2006) .
Our data on alkylation-induced ACF and apoptosis are consistent with the paradigm established by Sekiguchi and co-workers for thymic lymphoma formation in response to MNU (Kawate et al., 1998) . That is, mismatch repair deficiency relieves the short-term cytotoxic effects of O 6 MeG at the expense of grossly increased sensitivity to a carcinogenic end point. Our study contrasts somewhat with earlier reports showing that inhibition of Mgmt through the delivery of the inhibitor O 6 -benzylguanine had no effect on apoptosis induced by the S N 1 alkylating agents MNU and temozolamide in the mouse small intestine (Toft et al., 1999 (Toft et al., , 2000 . This discrepancy could result from the different alkylating agents used, the small intestine versus the colon, the use of a pharmacologic method versus a genetic method for eliminating Mgmt activity or a combination of these factors.
Mgmt status did not affect progression to adenomas following AOM treatment alone, nor did it affect intestinal tumor development on the Apc Min/ þ background. Other DNA repair deficiencies, including Msh2, Msh6, Mlh1, Pms2, Myh and Mbd4, result in more tumors on an Apc mutant background (either Min or 1638N) (Reitmair et al., 1996; Baker et al., 1998; Edelmann et al., 1999; Kuraguchi et al., 2001; Millar et al., 2002; Sieber et al., 2004) . They also cause a shift toward mutational loss of the wild-type allele of Apc away from the predominant mechanism for loss through mitotic recombination that normally occurs in C57BL6/J mice (Haigis et al., 2002) . Most of these mutants also show an increase in spontaneous mutation frequencies in the intestine in transgenic reporter mice such as Big Blue. In contrast, Mgmt deficiency causes no such increase in spontaneous mutation frequency (Sandercock et al., 2004) . We conclude that any endogenous formation of O 6 MeG that would be repaired by Mgmt is not sufficient to enhance tumor development in the experimental time frames that we examined.
Consistent with other studies, our results show that Mgmt deficiency strongly sensitizes to cancer development that is induced upon exposure to an alkylating carcinogen (Zaidi et al., 1995; Wali et al., 1999) . Human exposure to S N 1 type alkylating carcinogens can come in the diet, cigarette smoke, fuel combustion products, or the enzymatic nitrosation of amides and amines mediated by enteric bacteria (Sedgwick, 1997; Hecht, 1999) . Enterocytes that lose expression of MGMT would be significantly more sensitive to these exposures. Interestingly, promoter hypermethylation-dependent loss of Mgmt expression is more frequent in colorectal carcinomas than in adenomatous polyps or in normal mucosa (Nagasaka et al., 2008) . This silencing is associated with higher fractions of tumors with GC-AT transitions in KRAS2 and TP53, mutations thought to drive malignant progression in the colon (Vogelstein and Kinzler, 1993) . Therefore, it is possible that loss of MGMT expression during early tumor development sensitizes to malignant progression.
We showed that loss of mismatch repair and its ability to signal apoptosis dramatically sensitizes animals to the development of O 6 MeG-induced colon cancer precursor lesions, namely ACF. Interestingly, the mismatch repair gene MLH1 is also epigenetically silenced in almost half of sporadic colorectal cancers (Esteller et al., 2001) , but silencing of MLH1 and MGMT do not appear to occur in the same tumors (Fox et al., 2006) . Also, the ability of the O 6 MeG lesion to signal apoptosis involves p53-independent pathways (Hickman and Samson, 1999) . Our results clearly show that loss of the ability to signal apoptosis in response to O 6 MeG lesions dramatically sensitizes enterocytes to tumor formation. Thus, inactivation of O 6 MeG-initiated apoptosis may be an important step in human colorectal cancer development, particularly in those cancers that have lost expression of MGMT.
Materials and methods
Experimental animals
Targeted deletion within Mgmt was reported earlier (Glassner et al., 1999 (Edelmann et al., 1997) . These mutations have been backcrossed to the C57BL6/J strain for over 12 generations. C57BL6/J-Apc Min animals were purchased from the Jackson Laboratory (Bar Harbor, ME, USA).
Chemical carcinogenesis
Mice 6-8 weeks old were injected with AOM at doses from 1 to 12.5 mg/kg. For ACF studies, animals were euthanized by CO 2 asphyxiation 15 or 25 weeks after the treatment. Alternatively, 5 days after AOM treatment, mice were administered five cycles of 2.5% DSS in the drinking water; each cycle consisted of 5 days of DSS followed by 16 days of tap water. The protocol included the following exceptions: the last cycle was for 4 days and contained 2.0% DSS; also, the third cycle was stopped erroneously after 2 days and 5 days later the full 5-day treatment was administered. All animals receiving DSS were treated contemporaneously and were euthanized 4 or 5 days after the last cycle of DSS. Colons were removed from cecum to anus, flushed with cold phosphate-buffered saline, splayed open and fixed overnight in formalin. ACF and tumors were scored in whole mounts under a stereomicroscope after briefly staining in 1% methylene blue to provide contrast. Subsequently, colons were embedded as Swiss rolls for general pathology.
Spontaneous tumorigenesis in Apc
Min/ þ mice Apc Min/ þ mice were crossed with Mgmt À/À mice, and F 2 or F 3 generation littermates were used in tumor studies. The study was performed in two independent sets of crosses at different times with different Apc Min/ þ animals received from the Jackson Laboratory; the results from these independent experiments were analysed separately. Animals were euthanized at 130 days of age. Small intestines and colons were splayed open and fixed overnight in formalin. Tumors greater than 0.5 mm in diameter were enumerated under a stereoscope and measured with an ocular reticle. In addition, the position of each tumor along the length of the intestine was recorded. The nonparametric Mann-Whitney test was used to determine statistical differences in ACF or tumor multiplicities.
AOM-induced apoptosis
Mice were treated intraperitoneally with AOM at doses of 1, 5, 10 or 50 mg/kg and were sacrificed 24 or 48 h later. Colons were removed and flushed with ice cold phosphate-buffered saline, and the distended colons were fixed overnight in formalin. Cylinders were cut from the mid-to-distal colon and were used to score for apoptosis. Apoptoses were scored in hematoxylin and eosin-stained sections by morphological criteria (pyknotic nuclei, nuclear fragmentation, cytoplasmic blebbing). Regions from 3 or 4 cylindrical cross sections per animal were scored where high-quality crypt architecture was observed, and data are represented as apoptoses per crypt. Three to five animals were used per experimental group and the data from male and female mice were combined, as there were no gender differences. We scored a minimum of 250 crypts or 100 apoptotic events per animal. 
